Search
XTL-001
go.drugbank.com/drugs/DB05405InvestigationalXTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected
Sovateltide
go.drugbank.com/drugs/DB06138InvestigationalSPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. … It is being developed as an adjunct to chemotherapy.
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalThe specific marine organism is _Aplidium albicans_. Aplidine is also of interest as a potential treatment for some leukemias.
Dexpramipexole
go.drugbank.com/drugs/DB15130InvestigationalFrom the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)). … Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured
CEP-1347
go.drugbank.com/drugs/DB05403Investigationalprior to and after transplantation. … CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons
Cefotiam
go.drugbank.com/drugs/DB00229ApprovedOne of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
OMS-103HP
go.drugbank.com/drugs/DB05303InvestigationalOMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Lefradafiban
go.drugbank.com/drugs/DB04863InvestigationalLefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalIt is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760]. … Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
Aluminium monostearate
go.drugbank.com/drugs/DB01375ExperimentalAlso known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics. … Aluminium monostearate is a salt of stearic acid and aluminium with the molecular formula Al(OH)2C18H35O2.